Trial Profile
Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Rifapentine (Primary) ; Isoniazid; Rifampicin; Rifamycin
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASTERoiD
- 10 Jul 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2028.
- 10 Jul 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2028.
- 27 Dec 2021 Status changed from active, no longer recruiting to recruiting.